Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma

Anticancer Research

Volumn 25, Issue 6 A, 2005, Pages 3741-3746

  Goto, Shigenori ^a   Kaneko, Toru ^b   Miyamoto, Yoju ^b   Eriguchi, Masazumi ^b   Kato, Akira ^c   Akeyama, Teruhisa ^c   Fujimoto, Katsuhiro ^d   Tomonaga, Masamichi ^d   Egawa, Koji ^b  

^a Seta Clinic   (Japan)

^b Shin yokohama Medical Clinic   (Japan)

^c Kato Ryokuchi Koen Clinic   (Japan)

^d Fukuoka Medical Clinic   (Japan)

Author keywords

Adoptive immunotherapy; Dendritic cells; Immunocell therapy; Lymphocytes; Melanoma; Mixed response

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MONOCLONAL ANTIBODY CD3; NIMUSTINE; PEPTIDE DERIVATIVE; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; VINCRISTINE SULFATE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL LYSATE; CLINICAL ARTICLE; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMOBILIZED CELL; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR CELL; TUMOR LYSATE;

ADULT; AGED; ANTIGENS, NEOPLASM; DENDRITIC CELLS; EPITOPES; FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; MONOCYTES; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 27844587863     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Egawa K: Immuno-cell therapy of cancer in Japan. Anticancer Res 24: 321-326, 2004.
2. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA and Simpson C: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery 100: 262-272, 1986.
3. Anderson PM, Bach FH and Ochoa AC: Augumentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Cancer Immunol Immunother 27: 82-88, 1988.
4. Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K and Egawa K: Clinical benefit of non-toxic therapy in patients with advanced cancer (Opinion). Anicancer Res 22: 2461-2464, 2002.
5. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 356: 802-807, 2000.
6. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
7. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME and Weber J: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24: 66-78, 2001.
8. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA and Yamashita N: Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13: 521-530, 2003.
9. Garbe C: Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3: 291-299, 1993.
10. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
11. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
12. Egawa K: On the safety assurance of cell processing carried out in medical institutions for autologous immuno-cell therapy. Hum Cell 17: 1-6, 2004.
13. Kaneko T, Goto S, Kushima Y, Miyamoto Y, Eriguchi M, Nieda M and Egawa K: A report of three patients treated with immunocell therapy with imatinib mesylate. Anticancer Res 24: 3303-3309 2004.
14. Bianchi R, Grohmann U, Belladonna ML, Silla S, Fallarino F, Ayroldi E, Fioretti MC and Puccetti P: IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J Immunol 157: 1589-1597, 1996.
15. Grohmann U, Bianchi R, Fioretti MC, Fallarino F, Binaglia L, Uyttenhove C, Van Pel A, Boon T and Puccetti P: CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for turn- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 25: 2797-2802 1995.
16. Grohmann TJ, Bianchi R, Ayroldi E, Belladonna ML, Surace D, Fioretti MC and Puccetti P: A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol 158: 3593-3602, 1997.
17. Goto S, Sato M, Kaneko R, Itoh M, Sato S and Takeuchi S: Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunologic dysfunction in advanced cancer patients. Cancer Immunol Immunother 48: 435-442, 1999.
18. Barth A, Wanek LA and Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181: 193-201, 1995.